New York, USA, May 28, 2026 (GLOBE NEWSWIRE) — Synovial Sarcoma Clinical Trial Pipeline Accelerates as 15+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight
The synovial sarcoma clinical trial analysis report delivers important insights into ongoing research of 20+ pipeline synovial sarcoma drugs, clinical strategies, upcoming therapeutics, and commercial analysis.
DelveInsight’s ‘Synovial Sarcoma Pipeline Insight 2026’ report provides comprehensive global coverage of pipeline therapies for synovial sarcoma across various stages of clinical development. The report offers an in-depth analysis of key trends, emerging therapies, and competitive landscape dynamics, highlighting the strategies of major pharmaceutical companies to advance the pipeline and capitalize on future growth opportunities. In addition, it includes critical insights into clinical trial benchmarking, partnering and licensing activities, and regulatory pathways involving the FDA and EMA, enabling stakeholders to make informed decisions and optimize development strategies within the synovial sarcoma domain.
Synovial Sarcoma Clinical Trial Analysis Summary
- DelveInsight’s synovial sarcoma pipeline report depicts a robust space with 15+ active players working to develop 20+ pipeline synovial sarcoma drugs.
- Key synovial sarcoma companies, such as Takara Bio, Immatics, ModernaTX, Inc., Adaptimmune, Zelluna ASA, Daiichi Sankyo, Highlight Therapeutics, United Immunity, Valo Therapeutics, US WorldMeds, and others, are evaluating new synovial sarcoma drugs to improve the treatment landscape.
- Promising pipeline synovial sarcoma therapies, such as TBI-1301, IMA203 + mRNA-4203, ADP-600, ZI MA4 1, DS-2243a, BO-112, UI-201, PeptiCRAd-1, Lete-cel [NY-ESO], and others, are in different phases of synovial sarcoma clinical trials.
- Approximately 5+ synovial sarcoma drugs are in the mid and early stages of development.
- Notable MoAs in synovial sarcoma clinical trials include Immunologic cytotoxicity, T-cell redirected cytotoxicity, Anti-PRAME, Anti-MAGE-A4, and others.
Request a sample and discover the recent advances in synovial sarcoma drug development @ https://www.delveinsight.com/sample-request/synovial-sarcoma-pipeline-insight
What is Synovial Sarcoma?
Synovial sarcoma is a rare and aggressive type of soft tissue cancer that typically arises near the joints of the arms or legs, although it can also occur in other parts of the body, such as the lungs or abdomen. Despite its name, it does not originate from synovial tissue but is believed to develop from primitive mesenchymal cells. It most commonly affects adolescents and young adults and is characterized by a specific chromosomal translocation (SS18-SSX fusion gene), which plays a key role in its diagnosis. Clinically, it often presents as a slow-growing, deep-seated mass that may be painful or asymptomatic in early stages. Due to its high potential for local recurrence and metastasis, particularly to the lungs, synovial sarcoma requires a multidisciplinary treatment approach including surgery, radiation therapy, and sometimes chemotherapy.
Find out more about synovial sarcoma drug development @ Synovial Sarcoma Treatment
A snapshot of the Pipeline Synovial Sarcoma Drugs mentioned in the report:
| Drugs | Company | Phase | MoA | RoA |
| TBI-1301 | Takara Bio | III | Immunologic cytotoxicity | Intravenous |
| DS-2243a | Daiichi Sankyo | I | T-cell redirected cytotoxicity | Subcutaneous |
| IMA203 + mRNA-4203 | Immatics/ModernaTX, Inc. | I | Anti-PRAME | Infusion |
| ADP-600 | Adaptimmune | Preclinical | Anti-PRAME | NA |
| ZI MA4 1 | Zelluna ASA | Preclinical | Anti-MAGE-A4 | NA |
Learn more about the emerging synovial sarcoma therapies @ Synovial Sarcoma Clinical Trials
Stuti Mahajan, consulting manager at DelveInsight, said that synovial sarcoma remains a rare cancer with limited effective treatment options, which continues to drive strong unmet need and interest in targeted and immune-based therapies. The market is gradually shifting toward more precise approaches like TCR-T therapies and bispecific antibodies, with an expanding pipeline showing early clinical promise.
Recent Developments in Synovial Sarcoma Treatment Space
- In April 2026, Immatics announced that the company would be presenting updated Phase I study results with PRAME-directed T-cell receptor (TCR) T-cell therapies in synovial sarcoma.
- In February 2026, Zelluna announced that the Medicines and Healthcare products Regulatory Agency (MHRA) and Research Ethics Committee (REC) had approved the Company’s Clinical Trial Application (CTA) for ZIMA-101, a first-in-human Phase I clinical trial evaluating ZI-MA4-1, Zelluna’s lead TCR-NK product candidate.
- In December 2025, Zelluna announced the submission of its Clinical Trial Application (CTA) to the UK Medicines and Healthcare products Regulatory Agency (MHRA) for ZI-MA4-1. The Phase I clinical trial will evaluate ZI-MA4-1 in patients with advanced solid tumours, including synovial sarcoma.
- In September 2025, Takara Bio Inc. announced that the clinical trial notification for its investigational NY-ESO-1 siTCR™ gene therapy (TBI-1301; mipetresgene autoleucel) had been submitted to and accepted by Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), completing the required regulatory review and clearing the way for patient enrollment and dosing in a Phase III confirmatory study in unresectable advanced or recurrent synovial sarcoma.
- In June 2025, Valo Therapeutics Oy announced encouraging interim results from its ongoing Phase I clinical trial, START (Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer).
Scope of the Synovial Sarcoma Pipeline Report
- Coverage: Global
- Synovial Sarcoma Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
- Synovial Sarcoma Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Synovial Sarcoma Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Parenteral, Topical
- Synovial Sarcoma Therapeutics Assessment By Molecule Type: Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy
- Synovial Sarcoma Therapeutics Assessment By Mechanism of Action: Immunologic cytotoxicity, T-cell redirected cytotoxicity, Anti-PRAME, Anti-MAGE-A4, and others
- Key Synovial Sarcoma Companies: Takara Bio, Immatics, ModernaTX, Inc., Adaptimmune, Zelluna ASA, Daiichi Sankyo, Highlight Therapeutics, United Immunity, Valo Therapeutics, US WorldMeds, and others
- Key Synovial Sarcoma Pipeline Therapies: TBI-1301, IMA203 + mRNA-4203, ADP-600, ZI MA4 1, DS-2243a, BO-112, UI-201, PeptiCRAd-1, Lete-cel [NY-ESO], and others.
Dive deep into rich insights for new synovial sarcoma treatments, visit @ Synovial Sarcoma Drugs
Table of Contents
| 1. | Synovial Sarcoma Pipeline Report Introduction |
| 2. | Synovial Sarcoma Pipeline Report Executive Summary |
| 3. | Synovial Sarcoma Pipeline: Overview |
| 4. | Analytical Perspective In-depth Commercial Assessment |
| 5. | Synovial Sarcoma Clinical Trial Therapeutics |
| 6. | Synovial Sarcoma Pipeline: Late-Stage Products (Pre-registration) |
| 7. | Synovial Sarcoma Pipeline: Late-Stage Products (Phase III) |
| 8. | Synovial Sarcoma Pipeline: Mid-Stage Products (Phase II) |
| 9. | Synovial Sarcoma Pipeline: Early-Stage Products (Phase I) |
| 10. | Synovial Sarcoma Pipeline Therapeutics Assessment |
| 11. | Inactive Products in the Synovial Sarcoma Pipeline |
| 12. | Company-University Collaborations (Licensing/Partnering) Analysis |
| 13. | Key Companies |
| 14. | Key Products in the Synovial Sarcoma Pipeline |
| 15. | Unmet Needs |
| 16. | Market Drivers and Barriers |
| 17. | Future Perspectives and Conclusion |
| 18. | Analyst Views |
| 19. | Appendix |
For further information on the synovial sarcoma cure research, reach out @ Medication for Synovial Sarcoma Treatment
Related Reports
Synovial Sarcoma Epidemiology Forecast
Synovial Sarcoma Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted synovial sarcoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Synovial Sarcoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key synovial sarcoma companies, including Viracta Therapeutics, Dizal Pharmaceuticals, CStone Pharmaceuticals, Rhizen Pharmaceuticals, Myeloid Therapeutics, Secura Bio, Kura Oncology, BeiGene, Celgene Corporation, BMS, Affimed, Innate Pharma, Otsuka Pharmaceutical, Astex Pharmaceuticals, Merck Sharp & Dohme Corp., and others.
Soft Tissue Sarcoma Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key STS companies, including Monopar Therapeutics, Jazz Pharmaceuticals, Moleculin Biotech, Inc., Advenchen Laboratories, LLC, Tracon Pharmaceuticals Inc., C4 Therapeutics, Inc., Eli Lilly and Company, Epizyme, Inc., Ipsen, GlaxoSmithKline, Salarius Pharmaceuticals, LLC, Mundipharma Research Limited, HiFiBiO Therapeutics, QBiotics Group Limited, Merck Sharp & Dohme LLC, Polaris Group, Philogen S.p.A., Agenus Inc, Apexigen America, Inc., Mirati Therapeutics Inc., and others.
Ewing Sarcoma Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Ewing sarcoma companies, including Salarius Pharmaceuticals, Jazz Pharmaceuticals and Pharmamar, Eli Lilly, Pfizer, Bioatla, Cellectar Biosciences, Sumitomo Pharma Oncology, Inhibrx, and others.
Clear Cell Sarcoma Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key clear cell sarcoma companies, including Tesaro, NantPharma, Rafael Pharmaceuticals, Pfizer, and others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
